Literature DB >> 6645309

Theophylline elimination in congestive heart failure.

H D Kuntz, H Straub, B May.   

Abstract

The elimination of theophylline (clearance, half-life) was investigated in 50 patients with chronic congestive heart failure (grade III/IV) and in 20 controls. The cardiac diagnosis was based on clinical and hemodynamic parameters. Patients with congestion of the liver showed a significant reduction of the theophylline body clearance to 25.7 ml/kg/h +/- 12.1 vs 68.3 ml/kg/h +/- 14.8 in the control group, and a corresponding prolongation of the half-life to 5.7 h +/- 2.5 vs 3.1 h +/- 1.4 in the control group. The main pathogenetic factor is obviously the functioning hepatic tissue, reflected by the galactose elimination capacity (r = 0.666; P less than 0.01; theophylline clearance vs galactose elimination capacity).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6645309     DOI: 10.1007/BF01496473

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes.

Authors:  S M RICHMAN; A J DELMAN; D GROB
Journal:  Am J Med       Date:  1961-02       Impact factor: 4.965

2.  LIVER FUNCTION IN CONGESTIVE HEART FAILURE.

Authors:  N Jolliffe
Journal:  J Clin Invest       Date:  1930-04       Impact factor: 14.808

3.  "Cardiac" or congestive cirrhosis of liver.

Authors:  P KOTIN; E M HALL
Journal:  Am J Pathol       Date:  1951 Jul-Aug       Impact factor: 4.307

Review 4.  The liver in congestive heart failure: a review.

Authors:  G D Dunn; P Hayes; K J Breen; S Schenker
Journal:  Am J Med Sci       Date:  1973-03       Impact factor: 2.378

5.  Galactose tolerance test of liver function in pulmonary heart disease.

Authors:  A J Thomas; R A Saunders
Journal:  Br Heart J       Date:  1969-01

6.  The liver when the heart fails.

Authors:  A J Ware
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

Review 7.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

8.  Theophylline kinetics in acute pulmonary edema.

Authors:  K M Piafsky; D S Sitar; R E Rangno; R I Ogilvie
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

9.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

10.  Left-sided heart failure presenting as hepatitis.

Authors:  J A Cohen; M M Kaplan
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

View more
  9 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  [Pharmacokinetics and pharmacodynamics of theophylline in geriatric patients with multiple diseases].

Authors:  W Mühlberg; D Platt; M Bauer; U Salzner
Journal:  Klin Wochenschr       Date:  1987-07-15

Review 3.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

4.  Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.

Authors:  Rocco Orlando; Sara De Martin; Laura Andrighetto; Maura Floreani; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 5.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 7.  Pharmacokinetic changes in patients with oedema.

Authors:  B Vrhovac; N Sarapa; I Bakran; M Huic; V Macolic-Sarinic; I Francetic; A Wolf-Coporda; F Plavsic
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

8.  Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.

Authors:  Shizuka Yamaura; Miki Fukao; Kazuya Ishida; Masato Taguchi; Yukiya Hashimoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-06       Impact factor: 2.441

9.  Case Report: The risks associated with chronic theophylline therapy and measures designed to improve monitoring and management.

Authors:  Michael E Hopkins; Robert V MacKenzie-Ross
Journal:  BMC Pharmacol Toxicol       Date:  2016-03-05       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.